Genzyme Canada HomeGenzyme Corporate HomeSearchContact UsGenzyme Websites
Corporate InfoOur Therapies and Products
English  |  Français

Health Care Professionals and Patients:
Research our treatment areas and services for your medical condition and health care practice More >
  Learn about our Canadian operations.  
  Explore opportunities in our entrepreneurial culture.  
  Find out about what is new in our research and development.  
  View a calendar of our events.  
  See what's new for Genzyme in Canada.  


First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada
Mississauga, ON - Genzyme, a Sanofi company, today announced the Canadian availability of PrLEMTRADA™ (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. More>

Health Canada Approves Genzyme’s AUBAGIOŽ (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Remitting Multiple Sclerosis
Mississauga, ON - Genzyme, a Sanofi company, announced today that Health Canada has approved AUBAGIOŽ (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. More>

MS Society Walks – Genzyme Canada involved in the fight to end MS
Genzyme made the decision to support the MS Society’s Walk, no doubt, at the same time Norma Beauchamp was hired as the Director of the MS Business Unit. Norma’s passions for patient focused activities lead us to these events. This decision was the right one to make and it allowed us to develop a strong relationship with the MS Society at the National, Ontario & Quebec levels. More>


Subscribe | Privacy Policy - Canada USA | Terms and Conditions of Use | | © 2003-2014 Genzyme, a Sanofi company. All rights reserved.